# Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.

> **NCT05378997** · PHASE1 · COMPLETED · sponsor: **Xinnate AB** · enrollment: 35 (actual)

## Conditions studied

- Blister
- Wound of Skin
- Epidermolysis Bullosa
- Varicose Ulcer of Lower Limb

## Interventions

- **DRUG:** TCP-25 gel 0.86 mg/ml or placebo gel
- **DRUG:** TCP-25 gel 2.9 mg/ml or placebo gel
- **DRUG:** TCP-25 gel 8.6 mg/ml or placebo gel

## Key facts

- **NCT ID:** NCT05378997
- **Lead sponsor:** Xinnate AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-07
- **Primary completion:** 2024-03-16
- **Final completion:** 2024-03-16
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05378997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05378997, "Safety, Tolerability, and Pharmacokinetics of Ascending Topical Doses of TCP-25 Applied to Epidermal Suction Blister Wounds, Non-Healing Leg Ulcers and Patients With Dystrophic Epidermolysis Bullosa.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05378997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*